ProMIS Neurosciences (PMN) Evercore ISI 8th Annual HealthCONx Conference summary

State of the business and industry

• Focused on advancing a phase I-B clinical study for Alzheimer's, with consistent progress and guidance maintained throughout the year.

• The Alzheimer's treatment landscape remains open for novel drugs due to limitations and side effects of current market options.

• Enrollment for the phase I-B trial is on track to complete by year-end, with interim analysis expected in Q2 and top-line results in Q4 of the following year.

• The lead asset, PMN310, is an amyloid beta monoclonal antibody targeting toxic oligomers rather than plaque.

Scientific rationale and differentiation

• Industry focus has shifted from targeting amyloid plaque to toxic oligomers, which are now seen as the main drivers of disease progression.

• PMN310 is designed to selectively target low molecular weight oligomers, believed to be the most toxic species.

• Competing drugs often cross-react with plaque, leading to side effects like ARIA, while PMN310 aims to minimize this risk.

Clinical trial design and safety

• The phase I-B PRECISE-AD trial targets 128 patients to ensure at least 100 completers, with three dosing cohorts (5, 10, 20 mg/kg).

• Safety profile has been strong, with ARIA rates expected to be similar to placebo and lower than other drugs.

• Interim analysis will focus on safety and biomarker endpoints, not direct clinical efficacy.

• Biomarkers such as pTau217, pTau243, neurogranin, GFAP, and SNAP-25 will be used to infer potential clinical benefit.